Цель. Изучить взаимодействие сывороточного галектина-3 (Г-3) с фиброгенными факторами, ремоделированием сердца, а также показателями центральной гемодинамики при различных гемодинамических фенотипах хронической сердечной недостаточности (ХСН). Материал и методы. Обследовано 210 пациентов с ХСН обоего пола, средний возраст 64,1±1,4 лет. Диагноз ХСН был установлен на основании жалоб пациентов, анамнеза, объективного обследования и лабораторных исследований с использованием рекомендаций Европейского общества кардиологов по диагностике и лечению ХСН (2016). Помимо общепринятых лабораторно-инструментальных исследований, были проведены иммуноферментные анализы: сывороточный Г-3, альдостерон, матриксная металлопротеиназа-1 (ММП-1), тканевой ингибитор матриксной металлопротеиназы-1 (ТИМП-1). Результаты. Пациенты были разделены на две группы: I группа состояла из 59 пациентов со сниженной фракцией выброса (ФВ) левого желудочка (ЛЖ) (ФВ ЛЖ <40%), II группа -56 пациентов с промежуточной ФВ ЛЖ (ФВ ЛЖ 41-49%) и III группа состояла из 95 пациентов с сохраненной ФВ ЛЖ (ФВ >50%). Референсные значения биологически активных веществ в сыворотке крови пациентов составили:

In the article, iron deficiency associated with Helicobacter pylori is associated with a number of external factors and bad habits in the development of anemia. Helicobacter pylori should be tested in all patients with chronic iron deficiency anemia and gastrointestinal complaints. In patients diagnosed with Helicobacter pylori-associated iron-deficiency anemia, it has been shown to have a highly reliable effect of first carrying out antibacterial eradication therapy and then prescribing an iron supplement according to the severity of the disease.

Aim of the study: To examine the state of the gastrointestinal organs of patients, recovered from Covid-19 using indicators of calprotectin and Helicobacter pylori in feces and interleukin-6 in blood, as well as improvement of the treatment. Materials and methods of the study: In accordance with the aim of the study, 100 patients with gastrointestinal symptoms were observed. 42 of them (42%) were men and 58 (58%) were women. Patients were divided into 2 groups. The first group consisted of patients "relatively recovered" from Covid-19 with no detected immunoglobulin M but with gastrointestinal symptoms (27 men and 33 women; average age 55.06±2.1 years). The second, i.e. control group, consisted of patients, who did not have Covid-19 but had gastrointestinal symptoms (15 men and 25 women; average age 63.4±1.5 years). The levels of calprotectin and H. pylori in feces as well as interleukin-6 in the blood of patients involved in the study were measured.Conclusion. Although positive results were observed after the complex treatment in all groups, in all cases, where patients received rebamipide, changes were more evident. In the group receiving rebamipid a reliable decrease in inflammatory processes in the body of the patients, including the gastrointestinal system was also observed. This was shown by a decrease in calprotectin and H.pylori in their feces and interleukin-6 in their blood.

It has been shown in several scientific works that Helicobacter pylori is not distributed uniformly in different countries of the world and that ethnic, geographical factors, genetic predisposition, sanitary-hygienic condition in the region and family, diet play an important role in its development. In this article, the level of Helicobacter pylori antibodies in the blood of patients was analyses in relation to on a number of external factors, in particular, harmful habits (cigarette smoking and nas consumption), eating habits, the presence of central water supply and sewerage at the place of residence. Moreover, it has been confirmed that negative factors cause an increase in the level of Helicobacter pylori antibodies in the blood.